Till startsida
To content Read more about how we use cookies on gu.se

EU Projects


European Medical Information Framework



An Innovative Medicines Initiative (IMI) Joint Undertaking project supported by the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Grant agreement no. 115372

Project time: 1 January 2013 - 31 December 2017


Project time: 1 November 2009 - 31 October 2015

SUMMIT is a pan-European research consortium that receives support from the Innovative Medicines Initiative (IMI). It aims at identifying markers that predict the risks of developing diabetes chronic micro- and macro-vascular complications with focus on Diabetic Nephropathy (DN), Diabetic Retinopathy (DR), and Cardiovascular disease (CVD).


European Network on Functional Genomics of Type 2 Diabetes

Project time: 1 November 2004 - 30 April 2009

EUGENE2 is an EU-supported network of renowned European laboratories that investigate the causes and consequenes of Type 2 diabetes. The network comprises laboratories from Sweden, Finland, Denmark, Italy, Germany, Great Britain, France and Spain. The Coordinator is Prof. Ulf Smith.

The project is completed 30 April 2009.



Hepatic and Adipose Tissue and Functions in the Metabolic Syndrome

The project is completed 31 Oct 2010





EMIF-Metabolic WP Network

EMIF - European Medical Information Network

IMI Call topic: IMI Call 2011

"A European Medical Information Framework (EMIF) of patient-level data to support a wide range of Medical research".

Objective 1: Establishment of the Information Framework (EMIF-Platform). Topic Leader: Johan van der Lei, Erasmus University, Rotterdam, Netherlands and Patrick Genyn Janssen Pharmaceutica NV, Beerse, Belgium

Objective 2: Identification of prognostic and diagnostic biomarkers for Alzheimer's Disease (EMIF-AD). Topic Leader: Pieter Jelle Visser, VU Medical Center, Amsterdam and Mike Krams, Janssen Pharmaceutica NV, Beerse, Belgium

Objective 3: The identification of predictors and diagnostic markers of metabolic complications in adults and paediatrics (EMIF-Metabolic). Topic Leader: Ulf Smith, University of Gothenburg, Sweden and Dawn M. Waterworth, Glaxo Smith Kline, Upper Merion, PA, USA


Page Manager: Gunilla Lindell|Last update: 10/29/2015

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?